Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws

What Was Tested

Researchers studied Teriparatide in this clinical trial publication.

To review the effect of teriparatide as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws (BRONJ), the researchers describe a series of cases of teriparatide therapy for the treatment of BRONJ and serial changes of serum osteoclacin (s-OC) and serum C-terminal telopeptide cross-link of type I collagen (s-CTX).

Management of BRONJ is quite challenging and the currently recommended modalities for BRONJ are still suboptimal.

Who Took Part

The age groups tagged for this paper are people over 80, both men and women.

Bisphosphonate was suspended and teriparatide was given to six patients diagnosed with BRONJ by single bone specialist.

The outcome of the treatment and the change of biochemical markers were compared.

How the Study Was Run

Medical record review and interviews were carried out.

S-CTX and s-OC were measured at the baseline, 2 months and 3 months later teriparatide therapy.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents, Chemotherapy, Adjuvant, Collagen Type I, Osteocalcin and Peptides.

What This Means in Plain Language

This is a clinical trial of Teriparatide.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, all human trials.